86 related articles for article (PubMed ID: 7618043)
21. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
[TBL] [Abstract][Full Text] [Related]
22. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
23. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
Leikis MJ; Kent AB; Becker GJ; McMahon LP
Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
[TBL] [Abstract][Full Text] [Related]
24. Erythropoietin with oral iron in peritoneal and hemodialysis patients. A comparison in an inner city population.
Raja R; Bloom E; Goldstein M; Johnson R
ASAIO J; 1993; 39(3):M578-80. PubMed ID: 8268603
[TBL] [Abstract][Full Text] [Related]
25. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group).
Muirhead N; Laupacis A; Wong C
Nephrol Dial Transplant; 1992; 7(8):811-6. PubMed ID: 1325613
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of anemia in patients after long term hemodialysis with human recombinant erythropoietin].
Boratyńska M; Mazanowska O; Szewczyk Z
Pol Merkur Lekarski; 1996 Nov; 1(5):329-31. PubMed ID: 9273209
[TBL] [Abstract][Full Text] [Related]
27. The beneficial effect of low initial dose and gradual increase of erythropoietin treatment in hemodialysis patients.
Walter J; Gål J; Taraba I
Artif Organs; 1995 Jan; 19(1):76-80. PubMed ID: 7741644
[TBL] [Abstract][Full Text] [Related]
28. Correction of anemia in patients on continuous ambulatory peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: a long-term study.
Cheng IK; Cy C; Chan MK; Yu L; Fang GX; Wei D
Clin Nephrol; 1991 May; 35(5):207-12. PubMed ID: 1855328
[TBL] [Abstract][Full Text] [Related]
29. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin.
Barclay PG; Fischer ER; Harris DC
Clin Nephrol; 1993 Nov; 40(5):277-80. PubMed ID: 8281716
[TBL] [Abstract][Full Text] [Related]
30. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis.
Lai KN; Lui SF; Leung JC; Law E; Nicholls MG
Nephron; 1991; 57(4):394-400. PubMed ID: 1828543
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy and safety of long-term erythropoietin therapy in chronic hemodialysis patients with renal anemia].
Ohkubo M; Ishimitsu T; Kawaguchi T; Abe M; Yagi S
Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):171-7. PubMed ID: 8315880
[TBL] [Abstract][Full Text] [Related]
32. [Arterial hypertension in patients with chronic kidney insufficiency in hemodialysis with erythropoietin].
Martins Prata M; Teixeira de Sousa F; Barbas J; Vinhaś J; Marques da Costa A
Rev Port Cardiol; 1990 Feb; 9(2):119-23. PubMed ID: 2346662
[TBL] [Abstract][Full Text] [Related]
33. [Erythropoietin administration to preterm infants: comparison between subcutaneous and intravenous route].
Rigourd V; Kieffer F; Dommergues MA; Ayachi A; Assaf Z; Mohamed I; Voyer M; Magny JF
Arch Pediatr; 2004 Apr; 11(4):319-26. PubMed ID: 15051090
[TBL] [Abstract][Full Text] [Related]
34. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
[TBL] [Abstract][Full Text] [Related]
35. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
Lui SF; Law CB; Ting SM; Li P; Lai KN
Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
[TBL] [Abstract][Full Text] [Related]
36. Effect rHuEpo on predialysis CRF patients: study of 45 cases.
Islam S; Rahman H; Rashid HU
Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):83-7. PubMed ID: 16967814
[TBL] [Abstract][Full Text] [Related]
37. [Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis].
Vanková S; Safárová R; Horácková M; Herink J; Rychlík I; Bahbouh R; Půtová I
Cas Lek Cesk; 2001 Apr; 140(7):209-13. PubMed ID: 11374225
[TBL] [Abstract][Full Text] [Related]
38. Erythropoietin associated hypertension among pediatric dialysis patients.
Komatsu Y; Ito K
Adv Perit Dial; 1992; 8():448-52. PubMed ID: 1361845
[TBL] [Abstract][Full Text] [Related]
39. Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy.
Caravaca F; López-Minguez JR; Arrobas M; Cubero J; Pizarro JL; Cid MC; Sanchez-Casado E; Miranda MP
Nephrol Dial Transplant; 1995; 10(9):1720-4. PubMed ID: 8559495
[TBL] [Abstract][Full Text] [Related]
40. Effects of dialysis factors and route of administration on response of hemodialysis patients to recombinant human erythropoietin.
Besarab A; Besarab FM; Miller D
ASAIO Trans; 1991; 37(3):M181-2. PubMed ID: 1751101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
